Hairy cell leukaemia recurrent – Diagnostics – Overview of Information and Clinical Research

Hairy cell leukemia that comes back after treatment requires careful monitoring and specialized testing to guide the next steps in care. Understanding the diagnostic process helps patients know what to expect during follow-up visits and relapse assessment.

Introduction: Who Should Undergo Diagnostics

When hairy cell leukemia returns after an initial successful treatment period, doctors need to perform thorough testing to confirm the relapse and determine the best treatment approach. Patients who previously achieved remission typically see their medical team every three to six months for routine monitoring, even when they feel well. During these regular checkups, blood tests help doctors detect early signs that the disease may be returning before symptoms become noticeable.^[1]

You might need more detailed diagnostic testing if your routine blood work shows changes in your blood cell counts, or if you begin experiencing symptoms such as fatigue, frequent infections, or discomfort in your abdomen. Sometimes doctors discover a relapse through routine monitoring even before any symptoms appear. This early detection can be very helpful in planning the timing and type of treatment you may need.^[4]

Not everyone who previously had hairy cell leukemia needs immediate testing. If you remain in remission (a state where the disease is not active and causing no symptoms), your doctor will continue with scheduled monitoring appointments. However, if you notice new symptoms or if your blood counts drop during routine checks, your healthcare provider will recommend diagnostic tests to understand what is happening in your body.^[7]

Understanding when to seek diagnostics is especially important for patients who have already been through treatment. Living with the knowledge that hairy cell leukemia can return creates uncertainty, but regular monitoring and prompt testing when needed help manage this chronic condition effectively. The time between remission and relapse varies greatly from person to person, with some experiencing months and others enjoying years without disease activity.^[9]

Diagnostic Methods for Identifying Recurrent Disease

When doctors suspect that hairy cell leukemia has returned, they use several proven methods to confirm the diagnosis and assess the extent of the relapse. The diagnostic process typically begins with straightforward blood tests and may progress to more detailed examinations depending on what the initial results reveal.^[3]

Complete Blood Count and Blood Smear

A complete blood count (CBC) is usually the first test performed when relapse is suspected. This test measures the number of red blood cells, white blood cells, and platelets in your blood sample. It also checks the amount of hemoglobin (the protein in red blood cells that carries oxygen throughout your body). When hairy cell leukemia returns, these blood cell counts often become abnormal again, showing patterns similar to when you were first diagnosed.^[3]

Doctors also examine a peripheral blood smear, where laboratory specialists place a drop of your blood on a glass slide and look at it under a microscope. They search for the distinctive “hairy” cells that give this leukemia its name. These abnormal cells have thin projections extending from their surface that look like hairs. The blood smear also helps identify a reduction or absence of monocytes (a type of white blood cell), which is a characteristic finding in hairy cell leukemia. However, the absence of hairy cells in the blood does not rule out relapse, as sometimes these cells remain only in the bone marrow.^[2]

⚠️ Important

Finding hairy cells in your blood doesn’t automatically mean you need treatment right away. Your doctor will consider your overall blood counts, symptoms, and how you feel before recommending any action. Some patients with detectable disease can continue with watchful waiting rather than immediate treatment.

Bone Marrow Biopsy

A bone marrow biopsy provides the most reliable information about whether hairy cell leukemia has returned. During this procedure, your doctor uses a thin, hollow needle to remove small samples of bone marrow or bone tissue, usually from your hip bone. The sample is then examined in a laboratory to look for abnormal, hairy B-cells. This test is particularly important because hairy cells may be present in the bone marrow even when they don’t appear in the blood.^[5]

The bone marrow in hairy cell leukemia is often fibrotic (containing excess fibrous tissue), which can make it difficult to aspirate or draw out marrow fluid. Because of this, doctors may need to take a core biopsy, which removes a small cylinder of bone and marrow together. Although this test sounds uncomfortable, your medical team can provide pain relief and anxiety medications if you feel overwhelmed about having it done. Many patients find it helpful to have a family member present during the procedure for emotional support.^[6]

Immunophenotyping and Flow Cytometry

Immunophenotyping is a laboratory technique that uses special antibodies to identify cells based on markers on their surface. This test is extremely useful in diagnosing relapsed hairy cell leukemia because the abnormal cells have a very specific pattern of markers. In classic hairy cell leukemia, the cells test positive for several markers including CD19, CD20, CD11c, CD25, CD103, and CD123. The presence of these markers together confirms the diagnosis and helps distinguish hairy cell leukemia from other similar blood cancers.^[2]

Flow cytometry is the technology used to perform immunophenotyping. It can analyze thousands of cells quickly and identify physical or chemical changes in those cells. This test can be performed on blood or bone marrow samples and provides very detailed information about the type of cells present. The advantage of flow cytometry is that doctors can often make a diagnosis without needing a bone marrow biopsy, especially if hairy cells are circulating in the blood.^[7]

BRAF Gene Testing

Most people with hairy cell leukemia, more than 95 percent, have a specific genetic change called the V600E BRAF mutation. This mutation occurs in a gene that normally helps control cell growth, but the change causes B-cells to divide rapidly and become cancerous. Testing for this mutation can aid in confirming the diagnosis of relapsed hairy cell leukemia and can also help distinguish it from the variant form of the disease, which lacks this mutation.^[5]

The BRAF mutation test can be performed on blood or bone marrow samples. Finding this mutation not only confirms the diagnosis but also has implications for treatment, as some newer targeted drugs work specifically by blocking the abnormal protein produced by this mutated gene. This genetic testing has become an important tool in both diagnosis and treatment planning for patients with relapsed disease.^[6]

Physical Examination and Imaging

Your doctor will perform a physical examination to check for signs that hairy cell leukemia has returned. They will feel your abdomen to check if your spleen or liver is enlarged. An enlarged spleen occurs in more than 90 percent of patients with hairy cell leukemia and can cause discomfort in the upper left part of your abdomen. Your doctor may also check your lymph nodes in your neck, underarms, and groin for swelling, although enlarged lymph nodes are less common in hairy cell leukemia compared to other types of leukemia.^[5]

If your spleen or liver feels enlarged during the physical exam, your doctor may order imaging tests to better assess their size. A CT scan (computed tomography scan) or ultrasound of your abdomen can provide detailed pictures of these organs and nearby lymph nodes. These imaging tests are painless and help doctors understand how much the disease has affected different parts of your body. They also provide baseline measurements that can be used to monitor your response to treatment later.^[7]

Additional Blood Tests

Beyond the complete blood count, doctors may order additional blood tests to assess how the relapsed disease is affecting your body. These tests can check your liver and kidney function, look for signs of inflammation or infection, and measure various other components in your blood. Understanding your overall health status helps doctors choose the safest and most effective treatment approach if you need therapy for the relapsed disease.^[5]

Diagnostics for Clinical Trial Qualification

When considering participation in a clinical trial for relapsed or refractory hairy cell leukemia, additional diagnostic testing may be required beyond what is needed for standard diagnosis and treatment. Clinical trials have specific entry criteria to ensure that participants are suitable for the experimental treatment being studied and to maintain the scientific validity of the research.^[4]

Confirming Relapse or Refractory Disease

Clinical trials for relapsed hairy cell leukemia typically require documented evidence that the disease has returned after previous treatment, or that it did not respond adequately to initial therapy. This usually means you must have had at least one prior course of treatment. Doctors need to confirm through blood tests or bone marrow biopsy that hairy cells are present and that your blood counts meet certain criteria specified by the trial protocol.^[4]

Many trials require a bone marrow biopsy even if hairy cells are visible in your blood, to ensure accurate measurement of disease burden. The biopsy results provide a baseline that researchers can compare to later samples to determine how well the experimental treatment is working. While this may seem like an extra burden, this careful documentation helps advance medical knowledge about treating relapsed disease.^[13]

Measurable Residual Disease Testing

Measurable residual disease (MRD) testing looks for very small numbers of leukemia cells that remain after treatment, even when standard tests show complete remission. This highly sensitive testing uses techniques to detect the BRAF mutation or specific immunoglobulin gene rearrangements that are unique to each patient’s hairy cells. Some clinical trials use MRD testing to evaluate how deeply the experimental treatment clears the disease from your body.^[13]

MRD testing is performed on bone marrow or blood samples and can detect one leukemia cell among thousands or even millions of normal cells. While the role of MRD testing in making treatment decisions for hairy cell leukemia is still being studied, it provides researchers with valuable information about how well new therapies work. Patients participating in trials may have MRD testing at multiple time points during and after treatment.^[13]

Assessment of Overall Health and Organ Function

Clinical trials have eligibility requirements regarding your overall health to ensure you can safely receive the experimental treatment. This typically includes blood tests to check your kidney and liver function, as these organs process and eliminate many medications from your body. Your heart function may also be evaluated with an electrocardiogram (a test that records the electrical activity of your heart) or an echocardiogram (an ultrasound of your heart).^[4]

Trials may also require that you don’t have certain other medical conditions or that you haven’t received specific treatments within a certain time frame before joining the study. These requirements help protect your safety and ensure that any effects observed in the trial can be attributed to the experimental treatment rather than other factors. Your medical team will explain all the testing needed and help determine if a particular trial is right for your situation.^[4]

⚠️ Important

Hairy cell leukemia is rare, which means fewer clinical trials are available compared to more common types of cancer. However, doctors often work together across different countries to run trials and share information. Ask your specialist about whether any trials might be suitable for you, even if none are available at your local hospital.

Documentation of Previous Treatments

Clinical trials for relapsed disease require detailed information about what treatments you received previously, when you received them, and how you responded. This includes the names and doses of chemotherapy drugs, whether you received any targeted drugs or immunotherapy, and how long your remission lasted. Researchers need this information to understand which patients are most likely to benefit from the experimental treatment being studied.^[14]

You may need to provide medical records from previous treatment centers, and your current doctor may need to obtain pathology reports from past bone marrow biopsies. Organizing this information takes time, so if you’re interested in a clinical trial, it’s helpful to start gathering these records early in the process. Your medical team can assist you in obtaining the necessary documentation.^[4]

Prognosis and Survival Rate

Prognosis

The outlook for patients with relapsed hairy cell leukemia remains generally favorable, although the disease does tend to come back after treatment. Most people with hairy cell leukemia have a normal life expectancy with treatment, even when the disease relapses. When hairy cell leukemia returns, patients can usually achieve another remission with additional treatment. The overall hematological response rate after treatment for a first relapse is approximately 97 percent, with 86 percent of patients achieving complete disappearance of disease signs.^[14]

Several factors can influence the prognosis for patients with relapsed disease. The length of time between treatments matters—patients who relapse sooner after their last treatment may have a somewhat less favorable outlook than those who enjoyed many years of remission. Other factors that doctors consider include your age, blood counts at the time of relapse (particularly hemoglobin levels, platelet counts, and neutrophil counts), the presence of enlarged lymph nodes, and how large your spleen has become.^[6]

Around 50 percent of people in remission from hairy cell leukemia survive without the disease returning for ten years. However, hairy cell leukemia is a chronic condition that tends to relapse over time. As patients go through multiple relapses, the time to the next treatment tends to become shorter with each subsequent relapse. Despite this pattern, treatment strategies continue to be effective at controlling the disease and allowing patients to maintain good quality of life.^[12]

Some complications can affect prognosis. Patients with hairy cell leukemia have an increased risk of developing infections due to low white blood cell counts, which can be serious if not treated promptly. Additionally, there is a risk of developing a second cancer years after successful treatment for hairy cell leukemia. The five-year cumulative incidence of secondary cancers in patients with multiple relapses is approximately 12 percent. Regular monitoring helps detect these complications early.^[14]

Survival Rate

Patients with relapsed hairy cell leukemia have good survival rates overall. After third-line treatment (treatment for a second relapse), the median overall survival is 235 months, which is nearly 20 years. The five-year cumulative incidence of experiencing another relapse after third-line treatment is approximately 40 percent, with a median time before needing treatment again of 104 months (about eight and a half years).^[14]

For patients receiving fourth-line treatment (treatment for a third relapse), the overall hematological response rate remains high at 94 percent, showing that the disease continues to respond to treatment even after multiple relapses. The two-year cumulative incidence of experiencing yet another relapse after fourth-line treatment is 27 percent, indicating that while relapses become more frequent with each treatment cycle, many patients still enjoy extended periods without active disease.^[14]

For patients treated with newer targeted therapies such as vemurafenib (a drug that blocks the abnormal BRAF protein), overall survival at four years was 82 percent. However, relapse is common, with 68 percent of patients experiencing disease return at a median of 19 months after treatment. When patients were re-treated with vemurafenib after relapse, 86 percent had their white blood cell levels return to normal, demonstrating that repeated treatment with effective drugs remains an option.^[15]

Between 85 and 90 percent of people with hairy cell leukemia achieve complete remission with initial treatment, meaning all signs and symptoms of the disease disappear. Most people with hairy cell leukemia can expect to live a normal lifespan with appropriate treatment and monitoring. The slowly progressing nature of the disease, combined with effective treatments, allows most patients to maintain good quality of life even when the disease relapses.^[12]

#1 Clinical Trials Search in Europe